Preclinical study reveals cardiomyocyte-derived C-type natriuretic peptide limits myocardial ischaemic injury and fibrosis, indicating therapeutic potential for post-infarction tissue recovery.
C-type natriuretic peptide (CNP) is a significant player in the maintenance of cardiac and vascular homeostasis regulating local blood flow, platelet and leukocyte activation, heart structure and function, angiogenesis and metabolic balance. Since such processes are perturbed in myocardial infarction (MI), we explored the role of cardiomyocyte-derived CNP, and pharmacological administration of the peptide, in offsetting the pathological consequences of MI.
No takes yet. Share an insight, caveat, or question.
Lowe et al. (2024) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: